These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17538769)

  • 1. Nogo A protein neutralisation and motor cortex computer implants: a future hope for spinal cord injury.
    Alisky JM
    Singapore Med J; 2007 Jun; 48(6):596-7. PubMed ID: 17538769
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-Nogo on the go: from animal models to a clinical trial.
    Zörner B; Schwab ME
    Ann N Y Acad Sci; 2010 Jun; 1198 Suppl 1():E22-34. PubMed ID: 20590535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superman and the Swiss Continence Foundation.
    Dasgupta P
    BJU Int; 2015 Apr; 115 Suppl 6():1. PubMed ID: 25891315
    [No Abstract]   [Full Text] [Related]  

  • 4. Removing the brakes on post-stroke plasticity drives recovery from the intact hemisphere and spinal cord.
    Silasi G; Murphy TH
    Brain; 2014 Mar; 137(Pt 3):648-50. PubMed ID: 24549809
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-Nogo-A antibody: a treatment option for neurogenic lower urinary tract dysfunction?
    Schneider MP; Schwab ME; Kessler TM
    BJU Int; 2015 Apr; 115 Suppl 6():16-7. PubMed ID: 25430943
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-Nogo-A and training: can one plus one equal three?
    Starkey ML; Schwab ME
    Exp Neurol; 2012 May; 235(1):53-61. PubMed ID: 21530508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regenerating corticospinal fibers in the Marmoset (Callitrix jacchus) after spinal cord lesion and treatment with the anti-Nogo-A antibody IN-1.
    Fouad K; Klusman I; Schwab ME
    Eur J Neurosci; 2004 Nov; 20(9):2479-82. PubMed ID: 15525289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A.
    Weinmann O; Schnell L; Ghosh A; Montani L; Wiessner C; Wannier T; Rouiller E; Mir A; Schwab ME
    Mol Cell Neurosci; 2006; 32(1-2):161-73. PubMed ID: 16697217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Easing the brakes on spinal cord repair.
    McKerracher L; David S
    Nat Med; 2004 Oct; 10(10):1052-3. PubMed ID: 15459707
    [No Abstract]   [Full Text] [Related]  

  • 10. From bench to beside to cure spinal cord injury: lost in translation?
    Hug A; Weidner N
    Int Rev Neurobiol; 2012; 106():173-96. PubMed ID: 23211464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey.
    Freund P; Wannier T; Schmidlin E; Bloch J; Mir A; Schwab ME; Rouiller EM
    J Comp Neurol; 2007 Jun; 502(4):644-59. PubMed ID: 17394135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats.
    Liebscher T; Schnell L; Schnell D; Scholl J; Schneider R; Gullo M; Fouad K; Mir A; Rausch M; Kindler D; Hamers FP; Schwab ME
    Ann Neurol; 2005 Nov; 58(5):706-19. PubMed ID: 16173073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system.
    Buchli AD; Schwab ME
    Ann Med; 2005; 37(8):556-67. PubMed ID: 16338758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration.
    Xu G; Nie DY; Chen JT; Wang CY; Yu FG; Sun L; Luo XG; Ahmed S; David S; Xiao ZC
    J Neurochem; 2004 Nov; 91(4):1018-23. PubMed ID: 15525355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New treatments for spinal cord injuries].
    Salamanca F
    Gac Med Mex; 2002; 138(4):379-80. PubMed ID: 12200884
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular approaches to spinal cord repair.
    David S; Lacroix S
    Annu Rev Neurosci; 2003; 26():411-40. PubMed ID: 12626698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies neutralizing Nogo-A increase pan-cadherin expression and motor recovery following spinal cord injury in rats.
    Atalay B; Bavbek M; Cekinmez M; Ozen O; Nacar A; Karabay G; Gulsen S
    Spinal Cord; 2007 Dec; 45(12):780-6. PubMed ID: 17724451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction of the MASH1 gene into mouse embryonic stem cells leads to differentiation of motoneuron precursors lacking Nogo receptor expression that can be applicable for transplantation to spinal cord injury.
    Hamada M; Yoshikawa H; Ueda Y; Kurokawa MS; Watanabe K; Sakakibara M; Tadokoro M; Akashi K; Aoki H; Suzuki N
    Neurobiol Dis; 2006 Jun; 22(3):509-22. PubMed ID: 16497507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroscience. Animal studies raise hopes for spinal cord repair.
    Wickelgren I
    Science; 2002 Jul; 297(5579):178-81. PubMed ID: 12114604
    [No Abstract]   [Full Text] [Related]  

  • 20. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury.
    Kim JE; Liu BP; Park JH; Strittmatter SM
    Neuron; 2004 Oct; 44(3):439-51. PubMed ID: 15504325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.